Abstract:550 Background: Patients with muscle invasive urothelial carcinoma achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) have improved prognosis. Previously we did show that luminal tumors respond better to NACT (Ecke et al 2022), while the radioligand targets CXCR4 and FAP are found in chemoresistant, stroma-associated tumors. The objective of this study was to exploit the expression of CXCR4 & FAP for theranostic imaging & treatment in selected patients by radioligand instillation into the bladder to justify subsequent adopted clinical trials within the Bladder BRIDGister framework. Methods: FFPE tumor tissues from 511 TURB samples were prospectively collected as part of the Bladder BRIDGister. RNA was extracted by commercial kits, relative gene expression of subtyping markers and radioligand target genes were analyzed by RT-qPCR. Hierarchical clustering, Kruskal-Wallis and contingency tests were done by JMP 9.0.0 (SAS software). PET/CT Imaging by CXCR4 and/or FAP instillation was performed in selected patients followed by systemic radioligand application after completion of cisplatinum based NACT to enable improved staging. Results: The prospective molecular registry cohort consisted of 511 bladder cancer patients included into the Bladder BRIDGister (median age: 75, male 74% vs. female 26%) with 5% Tis, 54% Ta, 16% T1 and 15% T2 stage and concomitant CIS being in 7%. CXCR4 expression was negatively associated with ERBB2 & FGFR3 mRNA (r=-0,3021 and r=-0,3326, p<0,0001). Inverse relation of FAP expression with ERBB2 & FGFR3 was even more pronounced (r=-0,4883 and r=-0,5177, p<0,0001). Clustering validated that CXCR4 and FAP are elevated in non-luminal tumors not responding to NACT. Exemplarily one stromal rich pT2 G3 MIBC patient with elevated FAP expression, who was predicted to be unresponsive to NACT, was selected for FDG and FAP PET/CT imaging after two cycles of NACT. Indeed metastatic lesion were detected in the liver and pancreatic tissue. FAP imaging revealed to be more sensitive than conventional FDG imaging. In a next step 68 Ga-CXCR4 was instilled into the bladder of a patient with NACT-resistant MIBC rejecting cystectomy to establish a non-systemic approach for radioligand therapy. Theranostic instillation imaging revealed strong uptake into the invading MIBC and subsequent instillation therapy with 177 Lu-FAP led to partial remission and increased immune cell infiltration indicating initial effectivity. Conclusions: Expression of the radioligand targets CXCR4 and FAP are associated with aggressive stromal and basal like tumors being resistant to NACT. This could be validated by selecting patients for FAP & CXCR4 PET/CT imaging. Instillation of radioligands into the bladder revealed to be safe with first signs of effectivity justifying clinical approaches as part of phase 1 / 2 clinical trials.

Role of 64CuCl2 PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and 18F-FDG PET/CT

PET in bladder cancer imaging

Utility of fluoro-deoxy-glucose positron emission tomography (FDG-PET) to predict a pelvic lymph node involvement (LNI) in patients (pts) with muscle-invasive bladder cancer (MIBC) enrolled in neoadjuvant therapy trials.

11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer

Use of 18F‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients

Theranostic imaging and treatment of chemotherapy resistant muscle invasive bladder cancer by targeting FAP and CXCR4: The Bladder BRIDGister experience.

VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study

Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT

Assessing muscle invasion in bladder cancer via virtual biopsy: a study on quantitative parameters and classical radiomics features from dual-energy CT imaging

The role and effect of FDG-PET/CT on patient management and restaging of bladder carcinoma

Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT

The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature

Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach

Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results

Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI

Comparison of 99Mtc-3Prgd2 Integrin Receptor Imaging with 99Mtc-Mdp Bone Scan in Diagnosis of Bone Metastasis in Patients with Lung Cancer: a Multicenter Study.

Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.

Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer

Radiomics of Contrast-Enhanced Computed Tomography: A Potential Biomarker for Pretreatment Prediction of the Response to Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer

Prostate-specific membrane antigen SPECT-CT in patients with intermediate and high-risk prostate cancer in primary diagnosis: A comparative analysis with 18 F-PSMA PET/CT.